Art. 13 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 41×
1.

Without prejudice to Article 4(4) and (5) of Directive 2001/83/EC, a marketing authorisation which has been granted in accordance with this Regulation shall be valid throughout the Union. It shall confer the same rights and obligations in each of the Member States as a marketing authorisation granted by that Member State in accordance with Article 6 of Directive 2001/83/EC.

Authorised medicinal products for human use shall be entered in the Union Register of Medicinal Products and shall be given a number, which shall appear on the packaging.

2.

Notification of marketing authorisation shall be published in the Official Journal of the European Union, quoting in particular the date of authorisation and the registration number in the Union Register, any International Non-proprietary Name (INN) of the active substance of the medicinal product, its pharmaceutical form, and any Anatomical Therapeutic Chemical Code (ATC).

3.

The Agency shall immediately publish the assessment report on the medicinal product for human use drawn up by the Committee for Medicinal Products for Human Use and the reasons for its opinion in favour of granting authorisation, after deletion of any information of a commercially confidential nature.

The European Public Assessment Report (EPAR) shall include a summary written in a manner that is understandable to the public. The summary shall contain in particular a section relating to the conditions of use of the medicinal product.

4.

After a marketing authorisation has been granted, the holder of the authorisation shall inform the Agency of the dates of actual marketing of the medicinal product for human use in the Member States, taking into account the various presentations authorised.

The marketing authorisation holder shall notify the Agency if the product ceases to be placed on the market of a Member State, either temporarily or permanently. Such notification shall, other than in exceptional circumstances, be made no less than two months before the interruption in the placing on the market of the product. The marketing authorisation holder shall inform the Agency of the reasons for such action in accordance with Article 14b.

Upon request by the Agency, particularly in the context of pharmacovigilance, the marketing authorisation holder shall provide the Agency with all data relating to the volume of sales of the medicinal product at Union level, broken down by Member State, and any data in the holder's possession relating to the volume of prescriptions.

The 10 that are cited most themselves, of 41.

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    On 26 November 2013, the CHMP adopted the European Public Assessment Report (‘the EPAR’) for Tecfidera. The EPAR was published in accordance with Article 13(3) of Regulation No 726/2004. It contains a summary, written in a manner that …

    5 May 2021 · 62018TJ0611

  • Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 Novembe…Lawamends

  • Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination o…171820Law

    … Регистърът на лекарствените продукти на Съюза, предвиден в член 13, параграф 1 от Регламент (ЕО) № 726/2004, се актуализира съответно.

  • Regulation (EU) No 1027/2012 of the European Parliament and of the Council of 25 October…Lawamends

  • Order of the President of the General Court of 1 September 2015 (Extracts). Pari Pharma GmbH v European Medicines Agency.Decision

    Съгласно член 13, параграф 3 от Регламент № 726/2004, EMA публикува Европейския доклад за обществена оценка (наричан по-нататък „EPAR“) …

    1 Sep 2015 · 62015TO0235(01)

  • Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…1Law

    … продукт и количествата предписан продукт, както е предвидено в член 13, параграф 4 и член 38, параграф 4 от Регламент (ЕО) № 726/2004; 11. …

  • Judgment of the General Court (Second Chamber, Extended Composition) of 5 February 2018. Pari Pharma GmbH v European Medicines Agency.Decision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the EPAR, a summary of the characteristics of the medicinal products …

    5 Feb 2018 · 62015TJ0235

  • Judgment of the General Court (Third Chamber) of 14 December 2011. Nycomed Danmark ApS v European Medicines Agency (EMA).Decision

    It should be noted in that regard that, according to Article 8(3)(e) and Article 11 of Directive 2001/83, which are also applicable to applications for marketing authorisation provided for in Article 6 of Regulation No 726/2004, such …

    14 Dec 2011 · 62009TJ0052

  • Ordonnance du président du Tribunal du 20 juillet 2016. PTC Therapeutics International Ltd contre Agence européenne des médicaments.Decision

    Under Article 13(3) of Regulation No 726/2004, the EMA is to publish the European Public Assessment Report (‘EPAR’) on the medicinal product for human use drawn up by the CHMP, namely a summary of the product’s characteristics that …

    20 Jul 2016 · 62015TO0718(02)

  • Regulation (EU) 2019/5Lawamends